MedTrace Logo

Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure

NCT04677439 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-03-16

No results posted yet for this study

Summary

The purpose of this study is to explore the efficacy and safety of flumatinib in chronic phase of chronic myeloid leukemia (CML-CP) patients With Ph+ post imatinib failure.

Conditions

  • Flumatinib
  • Chronic Myeloid Leukemia, Chronic Phase
  • Imatinib

Interventions

DRUG

Flumatinib

600 mg of Flumatinib orally daily for 24 months

Sponsors & Collaborators

  • Hainan General Hospital

    collaborator OTHER

  • Sanya Central Hospital

    collaborator UNKNOWN

  • First Affiliated Hospital of Shantou University Medical College

    collaborator OTHER

  • Peking University Shenzhen Hospital

    collaborator OTHER

  • Dongguan People's Hospital

    collaborator OTHER_GOV

  • Shenzhen Second People's Hospital

    lead OTHER

Principal Investigators

  • Xin Du, Phd · Shenzhen Second People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2023-05-30
Completion
2023-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04677439 on ClinicalTrials.gov